Controversies in Urologic Cancer

How can you be sure you’ve selected the best approach for your patients with urologic cancer? As our experts debate developments like MRI fusion biopsy for PCa, HIFU for low-risk prostate cancer, and white light cystoscopy, learn how you can integrate these treatments into your practice.

Having trouble viewing? Click to downloadTrouble viewing this PDF?

Once you access the file, position your mouse over the top middle for a toolbar:

Related Content

Advertisement

April 10th 2018

Point: Is MRI fusion biopsy the new gold standard for diagnosis?

Studies provide clear evidence to support MRI fusion biopsy’s use as the gold standard for men at risk for prostate cancer diagnosis following an initial negative biopsy.

April 9th 2018

Counterpoint: Is MRI fusion biopsy the new gold standard for diagnosis?

Limitations of MRI fusion biopsy include its cost, interobserver variability, and low diagnostic accuracy for clinically significant cancer in the anterior prostate.

April 8th 2018

Point: Is HIFU for low-risk prostate Ca ready for prime time?

Evidence shows HIFU can provide cancer control outcomes comparable to those associated with radical prostatectomy or radiation therapy in properly selected patients.

April 7th 2018

Counterpoint: Is HIFU for low-risk prostate Ca ready for prime time?

Recommending either whole-gland or focal HIFU cannot be justified when their pros and cons are judged relative to the appropriate comparator.

April 6th 2018

Point: Is stand-alone white light cystoscopy a thing of the past?

Based on recent developments with blue light cystoscopy, the use of white light cystoscopy alone is now considered suboptimal as a diagnostic tool.

April 5th 2018

Counterpoint: Is stand-alone white cystoscopy a thing of the past?

More evidence is needed before blue light cystoscopy becomes the standard of care for diagnosis and treatment and renders white light cystoscopy obsolete.

Related Content

Advertisement

April 10th 2018

Point: Is MRI fusion biopsy the new gold standard for diagnosis?

Studies provide clear evidence to support MRI fusion biopsy’s use as the gold standard for men at risk for prostate cancer diagnosis following an initial negative biopsy.

April 9th 2018

Counterpoint: Is MRI fusion biopsy the new gold standard for diagnosis?

Limitations of MRI fusion biopsy include its cost, interobserver variability, and low diagnostic accuracy for clinically significant cancer in the anterior prostate.

April 8th 2018

Point: Is HIFU for low-risk prostate Ca ready for prime time?

Evidence shows HIFU can provide cancer control outcomes comparable to those associated with radical prostatectomy or radiation therapy in properly selected patients.

April 7th 2018

Counterpoint: Is HIFU for low-risk prostate Ca ready for prime time?

Recommending either whole-gland or focal HIFU cannot be justified when their pros and cons are judged relative to the appropriate comparator.

April 6th 2018

Point: Is stand-alone white light cystoscopy a thing of the past?

Based on recent developments with blue light cystoscopy, the use of white light cystoscopy alone is now considered suboptimal as a diagnostic tool.

April 5th 2018

Counterpoint: Is stand-alone white cystoscopy a thing of the past?

More evidence is needed before blue light cystoscopy becomes the standard of care for diagnosis and treatment and renders white light cystoscopy obsolete.